Invega paliperidone ER: Phase III data

In the 6-week, double-blind, international Phase III CR013099 trial in 311 patients, Invega met the primary endpoint of significantly improving PANSS scores vs. placebo (20 vs. 10.8, p<0.001). Invega ...